新股配售 | 貝康醫療-B一手中籤率10%,逾26.4萬人申購,公開認購402.8倍,國配21.8倍
uSMART盈立智投2月5日消息,貝康醫療-B公佈配售結果,並將於今日下午16:15-18:30分進行暗盤交易。
【配售小結】
①中籤率較快手、心通醫療高:與快手、心通醫療"撞車"招股,貝康醫療-B成了第三順位選擇,市場缺額度,打新者缺"子彈",最終申購人數約26.4萬人,不到心通醫療的一半。因此,中籤率整體較心通醫療、快手高,一手中籤率10%,申購200手穩中1手,甲尾穩1爭2,乙頭穩4爭5,頂頭槌中33手。
②國配貨源集中:國配認購倍數爲21.8倍,承配人總數爲112名,前25名承配人合共鎖定54.02%的發行股份(假設超額配股權未獲行使),貨源集中。
③暗盤漲多少:綜合多位市場人士的公開觀點,預計暗盤漲幅爲50%-100%。早前有傳聞貝康醫療場外暗盤錄得70港元成交,漲逾150%,不過,該消息未經證實。
uSMART盈立智投暗盤交易時間:2月5日16:15-18:30
【配售簡況】
1、發售價:27.36港元,爲招股價區間(26.36-27.36港元)的上限
2、一手市值:13680港元,每手500股
3、有效申購人數:264,120名(甲組:259,618名,乙組:4,502名)
4、實際中籤人數:37,626名
5、中籤情況:一手中籤率10%,申購200手穩中1手,甲尾穩1爭2,乙頭穩4爭5,頂頭槌中33手
6、公開認購倍數:402.8倍(甲組:311.4倍,乙組:494.1倍)
7、國配認購倍數:21.8倍,承配人總數爲112名,前25名承配人合共鎖定54.02%的發行股份
8、回撥情況:最大比例回撥,最終公開佔比爲50%,國配的佔比爲50%
9、超額配股權:於國際發售中,已超額分配1000萬股H股,有綠鞋
10、基石投資者:奧博資本、清池資本、CRF、AHAM等7名基石投資者,合共鎖定38.3%的發行股份,禁售期6個月
11、關聯客戶(2名):合共250,000股發售股份,約0.37%的發行股份,分配給華夏基金(香港)、中信證券
12、uSMART盈立智投暗盤交易時間:2月5日16:15-18:30
注:以上佔比均爲假設超額配股權未獲行使
【中籤詳情】
甲組:
一手中籤率10%
申購200手穩中1手
申購300手(甲尾)穩1爭2
乙組:
申購400手(乙頭)穩4爭5
申購500手中6手
申購600手中7手
申購700手中8手
……
申購6667手(頂頭槌)中33手
以下爲中籤分配基準:


【基石投資者】

【關聯客戶】

【禁售承諾】


【股權集中度】

點擊可跳轉閱讀《貝康醫療-B發售價及配發結果公告》原文件PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.